October 6, 2023Open Access

Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study

Key Points

Key points are not available for this paper at this time.

Abstract

FAP-targeted radioligand therapy with 177Lu-LNC1004 at 3.33 GBq/cycle was well tolerated in patients with advanced mRAIR-TC, with high radiation dose delivery to the tumor lesions, encouraging therapeutic efficacy, and acceptable side effects.

KI fragen

Bookmark

View Full Paper

Cite This Study

Fu et al. (Fri,) studied this question.

synapsesocial.com/papers/69de7fd61d9bba5129b0c35d https://doi.org/https://doi.org/10.1158/1078-0432.ccr-23-1983

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives2019 · 135 citations
2PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 20132016 · 192 citations
3Cancer-associated fibroblasts in papillary thyroid carcinoma2023 · 20 citations
4NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE2019 · 172 citations
5Clinical and therapeutic relevance of cancer-associated fibroblasts2021 · 1,268 citations

KI fragen

Bookmark

View Full Paper